OVERVIEW
This is part 3 of a 3-part Webinar series on bispecific antibodies (BsAbs) being developed for various hematologic malignancies. Part 3 addresses novel BsAbs being explored in clinical trials for follicular lymphoma (FL). Dr Gopal will explain how BsAbs work and review current data on their safety and efficacy. He will also discuss concerning treatment-related events of BsAbs and how to identify, prevent, and manage them. Finally, he will share his insights on how BsAbs might fit into the treatment paradigm for FL. Dr Gopal will finish up by answering your questions about BsAbs for FL.
GOAL STATEMENT
The goal of this activity is for learners to be better able to assess the current role of bispecific antibodies in the treatment of FL so that they can confidently anticipate how these new agents may be integrated into clinical practice.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Clinical trial data for bispecific antibodies in the treatment of FL [ITEM]Treatment-related adverse events of bispecific antibodies in the treatment of FL [/LIST] Demonstrate greater confidence in their ability to [LIST] [ITEM]Evaluate emerging data on bispecific antibodies for patients with FL [/LIST]
ACCREDITATION STATEMENT
[JALOGO][MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by independent educational grants from [bold]Genentech[/bold] and [bold] Regeneron Pharmaceuticals, Inc.[/bold]